Experimental Drug Slows Kidney Decline in Trial

Adults with IgA nephropathy saw less protein in their urine and stable kidney function over two years on telitacicept versus placebo.

Updated on Nov. 3, 2026 in Allergies

Bold flat-color editorial illustration of unlabeled glass vials in a rack beside a kidney-shaped form of translucent tubules on a cream background.
An experimental drug, telitacicept, slowed kidney decline and reduced protein leakage over two years in adults with IgA nephropathy in a phase 3 trial, though the drug is not yet approved in the United States. AI Illustration. Upload story photo >

A phase 3 trial of telitacicept, an investigational drug already approved in China for lupus, reduced protein leakage in the urine and stabilized kidney function over two years in adults with IgA nephropathy. The drug is not approved for use in the United States, and the results were presented at ASN Kidney Week in Denver.

Why it matters

IgA nephropathy is a leading cause of kidney failure, and most people with it have few effective disease-specific options, so a drug that slows kidney decline would matter for prevention and long-term care. The results are an interim look from a trial that is still ongoing, so they signal promise rather than settled practice.

This phase 3 randomized trial assigned adults with biopsy-confirmed IgA nephropathy 1:1 to weekly telitacicept or placebo, with results reported at 9 months and 2 years. Telitacicept reduced proteinuria by 55% versus placebo and produced a 5.1 mL/min/1.73 m² advantage in eGFR change, but the two-year results remain a trial interim look rather than a final conclusion.

The players

Peking University First Hospital

A major Beijing teaching hospital whose researchers presented the telitacicept IgA nephropathy findings at ASN Kidney Week.

ASN Kidney Week

The annual meeting of the American Society of Nephrology, a leading forum for kidney disease research and clinical trial results.

The details

Telitacicept is a dual antagonist of BAFF and APRIL, two signaling molecules that drive the immune activity responsible for the abnormal IgA1 antibodies that deposit in the kidneys in this disease. In the trial, patients received 240 mg weekly through week 39, then biweekly dosing from weeks 40 to 104. In the treated group, serum levels of galactose-deficient IgA1 fell by 47.8%, compared with a 19.1% change in the placebo group, and injection site reactions were more common with the drug.

Timeline

  1. Interim analysis at 9 months showed the 55% proteinuria reduction versus placebo.

  2. Stage A randomized treatment period ended at week 39.

  3. Final two-year eGFR outcome was measured at week 104.

Health Landscape

Telitacicept, already approved in China for systemic lupus erythematosus, is now being evaluated as a disease-modifying option for IgA nephropathy, a condition with limited targeted therapies. Its dual BAFF and APRIL blockade places it among newer immune-targeted approaches to kidney disease.

If you have IgA nephropathy, this is a development worth raising with your nephrologist, especially if you have persistent protein in your urine. Treatment decisions depend on your own kidney function and should be discussed with your physician rather than changed based on trial results alone.

The takeaway

Slowing kidney decline is the key goal in IgA nephropathy, and tracking urine protein and eGFR with your clinician is a practical way to monitor progress. Ask your doctor whether newer immune-targeted options may be relevant to your situation as trials continue.

Further reading

For background on how immune-driven conditions are treated, explore our Allergies coverage.